British startup iLoF offers a precise, patient-centric drug development platform.
British startup iLoF offers a precise, patient-centric drug development platform. The blood-based platform finds biological nanostructures in liquid dispersions such as plasma. The platform is rapid and non-invasive and facilitates the development of precise and personalized therapies. The startup’s screening test classifies patients for clinical trials.